Clinical trials: Resectable Hepatocellular Carcinoma
Hepatocellular Carcinoma Non-Resectable
Overcoming Immunotherapy Resistance in Hepatocellular Carcinoma
Each year, approximately 1,000 patients in the Netherlands are diagnosed with liver cancer. When liver cancer can no longer be treated with surgery or thermal ablation, cure is no longer possible.
- Trial name
- OvercomeHCC (NCT07895342)
- Testing
- External beam radiotherapy, transarterial radioembolization
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- Radboud University Medical Center
Hepatocellular Carcinoma, Resectable Hepatocellular Carcinoma
SBRT + Atezolizumab + Bevacizumab in Resectable HCC
This study is evaluating the safety and tolerability of neoadjuvant stereotactic body radiation therapy (SBRT) with atezolizumab and bevacizumab for treating resectable hepatocellular carcinoma.
- Trial name
- NCT04857684
- Testing
- Atezolizumab, Bevacizumab, Stereotactic Beam Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma
This is a prospective, single-blinded, single-arm, open-label Phase II trial of trans-arterial radiation segmentectomy using Yttrium-90 glass microspheres (TheraSphere®) for Hepatocellular Carcinoma (HCC) participants with…
- Conditions
- Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatocellular Carcinoma Non-resectable
- Trial name
- NCT07110233
- Testing
- TheraSphere® Yttrium-90 microspheres, Health Related Quality of Life Questionnaires (HRQOL)
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- University of California, San Francisco
Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Metastatic
Phase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs
ACE723 is a dual-payload antibody drug conjugate targeting glypican-3 (GPC-3) that is under investigation for the treatment of unresectable or metastatic hepatocellular carcinoma (HCC).
- Conditions
- Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Metastatic, Hepatocellular Carcinoma Non-Resectable
- Trial name
- NCT07861425
- Testing
- ACE723
- Where
- 2 sites in China
- Volunteers
- 70 people
- Sponsor
- Acepodia Biotech, Inc.
Resectable Hepatocellular Carcinoma With High Risk of Recurrence
Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence
The purpose of this study is to evaluate the impact of iparomlimab and tuvonralimab as preoperative neoadjuvant therapy on recurrence-free survival (RFS), along with its potential improvement in overall survival (OS), in patients…
- Trial name
- CCGLC-017 (NCT06954116)
- Testing
- Iparomlimab and Tuvonralimab (QL1706), Partial hepatectomy
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Tongji Hospital
Resectable Hepatocellular Carcinoma, Stage I Hepatocellular Carcinoma AJCC v8
Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer
This phase II trial studies the effect of atezolizumab and bevacizumab before surgery in treating patients with liver cancer that can be removed by surgery (resectable).
- Conditions
- Resectable Hepatocellular Carcinoma, Stage I Hepatocellular Carcinoma AJCC v8, Stage IA Hepatocellular Carcinoma AJCC v8, Stage IB Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT04721132
- Testing
- Atezolizumab, Bevacizumab, Therapeutic Conventional Surgery
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Resectable Hepatocellular Carcinoma
THIO and Cadonilimab in Resectable Hepatocellular Carcinoma
The goal of this clinical study is to find out if cadonilimab or ateganosine plus cadonilimab is effective and safe in treating resectable hepatocellular carcinoma (HCC).
- Trial name
- NCT07446257
- Testing
- ateganosine, Cadonilimab
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Texas Southwestern Medical Center
Hepatocellular Carcinoma Non-resectable
HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma
This is an open-label, single-arm, phase 2 study evaluating hepatic arterial infusion chemotherapy (HAIC) combined with lenvatinib and cadonilimab as conversion therapy for initially unresectable hepatocellular carcinoma (HCC).
- Trial name
- CCGLC-011 (NCT06187961)
- Testing
- Hepatic arterial infusion chemotherapy (HAIC-FOLFOX), Lenvatinib, Cadonilimab
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma Non-resectable
TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC
This study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization (TACE) combined with sintilimab and bevacizumab in patients with unresectable intermediate or advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT04592029
- Testing
- TACE combined with sintilimab and bevacizumab
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma
SIRT With Tremelimumab and Durvalumab for Resectable HCC
The goal of this research study is to evaluate the safety and tolerability of tremelimumab and durvalumab with or without Selective Internal Yttrium-90 Radioembolization (SIRT) in participants with resectable hepatocellular…
- Conditions
- Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Cancer
- Trial name
- NCT05701488
- Testing
- Durvalumab, Tremelimumab, SIRT
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Jiping Wang, MD, PhD
Hepatocellular Carcinoma Non-resectable
Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma
This prospective clinical trial will evaluate PET/CT and genomic liquid biopsy based biomarkers as predictors of clinical therapeutic response to immune-checkpoint inhibitor (ICI) therapy for patients with inoperable…
- Trial name
- ExTRACT-HCC (NCT04965454)
- Testing
- Fluorine-18 fluorocholine
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Queen's Medical Center
Hepatocellular Carcinoma Non-resectable
Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT
This study is conducted to evaluate the efficacy and safety of lenvatinib plus sintilimab, transarterial chemoembolization (TACE) with drug-eluting beads (DEB-TACE) and hepatic artery infusion chemotherapy (HAIC) with FOLFOX…
- Trial name
- NCT06904183
- Testing
- LEN+SIN+DEB-TACE+HAIC, LEN+SIN+DEB-TACE
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma Non-Resectable
Chemotherapy With the Ralox Regimen Combined With Anlotinib and Penpulimab for Unresectable Hepatocellular Carcinoma
The objective of this clinical trial study is to determine whether intravenous chemotherapy with the Ralox regimen in combination with Anlotinib and Penpulimab has certain efficacy and high safety for patients with unresectable…
- Trial name
- NCT07746960
- Testing
- Intravenous chemotherapy with the Ralox regimen combined with Anlotinib and Penpulimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Potentially Resectable Hepatocellular Carcinoma
Study on the Combined Treatment of Hepatocellular Carcinoma With Envafolimab, Suvemcitug and HAIC Conversion
This study is a single-center, exploratory clinical trial. Eligible patients with liver cancer, after signing the informed consent form, will be screened and enrolled.
- Trial name
- HCC (NCT07738055)
- Testing
- Envafolimab: 400mg, subcutaneous injection Suvemcitug: 2mg/kg, intravenous injection HAIC: Oxaliplatin 85mg/m² + 5-FU 2400-3200mg/m², continuous infusion, every 3 weeks
- Volunteers
- 35 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Resectable Hepatocellular Carcinoma
Phase Ib/II Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in Resectable HCC (Prophet)
The purpose of this phase Ib/II multicenter randomized control study is to investigate the efficacy and safety of peri-operative treatment with combination of CTLA-4, PD-1 antibodies and bevacizumab in resectable HCC
- Trial name
- NCT07714317
- Testing
- IBI310+ sintilimab + bevacizumab, IBI310+ sintilimab, sintilimab + bevacizumab
- Volunteers
- 90 people
- Sponsor
- Shanghai Zhongshan Hospital
Potentially Resectable Hepatocellular Carcinoma
Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)
The purpose of this phase 2/3 study is to investigate the efficacy and safety of camrelizumab combined with rivoceranib and hepatic arterial infusion chemotherapy (HAIC) as conversion therapy for Potentially Resectable HCC.
- Trial name
- NCT06796803
- Testing
- camrelizumab combined with rivoceranib and HAIC, camerlizumab + rivoceranib
- Where
- 2 sites in China
- Volunteers
- 398 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma Non-resectable
BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC)
The primary objective of the study is to confirm safety and technical success of BioPearl™ microspheres loaded with Doxorubicin in the treatment of unresectable hepatocellular carcinoma (HCC).
- Trial name
- BIOPEARL-ONE (NCT05911633)
- Testing
- BioPearl™
- Where
- 10 sites in Belgium, France and 2 more
- Volunteers
- 50 people
- Sponsor
- Terumo Europe N.V.
Resectable Hepatocellular Carcinoma
Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC
Study to evaluate the efficacy and safety of the combination of Atezolizumab and Bevacizumab as neoadjuvant plus adjuvant treatment in Hepatocellular Carcinoma.
- Trial name
- ASPIRE (NCT07018947)
- Testing
- Atezolizumab and Bevacizumab
- Where
- 12 sites in Spain
- Volunteers
- 90 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Hepatocellular Carcinoma Non-resectable
Selective Internal Radiation Therapy and 188Re-SSS Lipiodol Treatment for Liver Cancer (Lip-Re2)
The goal of this monocentric interventional study is to evaluate the efficacy, in terms of objective response rate, of the 188Re-SSS lipiodol SIRT in patients with non-operable HCC.
- Trial name
- Lip-Re2 (NCT05797870)
- Testing
- Selective Internal Radiation Therapy with 188Re-SSS lipiodol
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Center Eugene Marquis
Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk
A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma
This study is conducted to evaluate the efficacy and safety of SHR-8068 combined with Adebrelimab and Apatinib compared with Adebrelimab combined with Apatinib in perioperative treatment of resectable hepatocellular carcinoma…
- Trial name
- NCT07682272
- Testing
- SHR-8068 Injection, Adebrelimab Injection, Apatinib Mesylate Tablets
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.